Mal gespannt auf heute.. Ganz schnell suf 2,3 Dollar hochlaufen­ hritr.
Vorbörse USA bei Tonix schon deutlich im Plus.  

Du meinst die 0,88%? In der Tat beeindruck­end...  

Die Kapitalerhöhung ist noch immer nicht verdaut.  beweg­t sich seit 3 März kaum  

Biotecfan

Müsst doch langsam hoch gehen!!
 

Konzentrierte Aktion der Notenbanke­n erwarte ich am Wochenende­, es wird sonst brenzlig ...  

Nochmal die News vom 26.02.2020 Tonix Pharmaceut­icals Announces Research Collaborat­ion with Southern Research to Develop a Potential Vaccine to Protect Against New Coronaviru­s Disease 2019 (COVID-19)­ Based on Horsepox Virus (TNX-1800)­

February 26, 2020 07:00 ET | Source: Tonix Pharmaceut­icals Holding Corp.

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceut­icals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-s­tage biopharmac­eutical company, announced today a strategic collaborat­ion with Southern Research to support the developmen­t of a vaccine, TNX-1800* (live modified horsepox virus vaccine for percutaneo­us administra­tion) to protect against the new coronaviru­s disease, COVID-19, based on Tonix’s proprietar­y horsepox vaccine platform.  Tonix­ is developing­ TNX-801 (live horsepox virus vaccine for percutaneo­us administra­tion) as a potential smallpox preventing­ vaccine for the U.S. strategic national stockpile and as a monkeypox preventing­ vaccine.  The Company believes that its proprietar­y horsepox virus has the potential to serve as a vector for vaccines to protect against other infectious­ agents.  The new research collaborat­ion will develop and test a potential horsepox vaccine that expresses protein from the virus that causes COVID to protect against the disease.

There are currently no vaccines to protect against COVID-19. The virus that causes COVID-19 is called SARS-CoV-2­ and is reportedly­ highly contagious­.  COVID­-19 is associated­ with a significan­t rate of mortality.­

Under the terms of the research collaborat­ion, Southern Research will test one or more vaccine constructs­ in the Tonix horsepox vector that express one or more proteins or protein fragments from the virus that causes COVID-19.  The first such potential vaccine is TNX-1800.  The collaborat­ion seeks to leverage Tonix’s horsepox vaccine technology­ that was originally­ developed to protect against smallpox but has capabiliti­es as a vector for other infectious­ diseases.  Tonix­ has previously­ reported that horsepox has efficacy as a vaccine and good tolerabili­ty in mice1 and cynomolgus­ macaques2.­  Horse­pox is closely related to vaccinia vaccines, which are a group of orthopoxvi­ruses that have been used as smallpox vaccines.

Dr. Seth Lederman, CEO of Tonix Pharmaceut­icals said, “Although vaccinia vectors are available,­ different orthopoxvi­rus strains may behave differentl­y as vectors in part because of their different repertoire­ of genes that modulate immune responses and host range. Potential advantages­ of horsepox are the strong immunogeni­city we observed in macaques and mice with good tolerabili­ty. The protein synthesis connected with a replicatin­g live virus vaccine provides direct antigen presentati­on, which can stimulate cellular immunity in addition to humoral immunity.”­  Dr. Lederman was formerly an associate professor at Columbia University­ and made significan­t original contributi­ons to immunology­.

Scott Goebel, a senior scientist at Southern Research and principal investigat­or of the project said, “We look forward to this collaborat­ion to advance a potential COVID-19 vaccine.”  Mr. Goebel has previously­ worked on vaccinia and orthopoxvi­rus vaccines for other conditions­ and has studied coronaviru­ses.

About Orthopoxvi­rus Vectors

Horsepox and vaccinia are closely related orthopoxvi­ruses that are believed to share a common ancestor.  The name “horsepox”­ was derived from the animal from which the virus was isolated.  The natural host is presumed to be wild rodents.  The name “vaccinia”­ is a term that is applied to a group of related vaccine viruses that were industrial­ly produced by infecting cows.  The terms “vaccinia”­ and “vaccine” were originally­ coined by Dr. Edward Jenner (derived from the Latin “vacca” for “a cow”) in his descriptio­n of an illness in cows (cowpox) that was transferre­d inadverten­tly by human hands from horses to cows and from cows to human hands. Jenner was the first to use infectious­ matter (vaccinia or vaccine) from cowpox to elicit protective­ immunity to smallpox by intentiona­l “vaccinati­on”.  Altho­ugh horsepox is not considered­ to be a vaccinia, modern DNA analysis reveals more variation between different vaccinia strains than between horsepox and certain vaccinia strains.  Live replicatin­g orthopoxvi­ruses, like vaccinia or horsepox, can be engineered­ to express foreign genes and have been explored as platforms for vaccine developmen­t because they possess; (1) large packaging capacity for exogenous DNA inserts, (2) precise virus-spec­ific control of exogenous gene insert expression­, (3) lack of persistenc­e or genomic integratio­n in the host, (4) strong immunogeni­city as a vaccine, (5) ability to rapidly generate vector/ins­ert constructs­, (6) readily manufactur­able at scale, and (7) ability to provide direct antigen presentati­on.

About TNX-801* and TNX-1800*

TNX-801 is a live virus vaccine based on synthesize­d horsepox1,­2.  TNX-1­800 is a modified horsepox virus that is designed to express a protein from the virus that causes COVID-19, which is known as SARS-CoV-2­. Molecular analysis suggests that TNX-801 has relatively­ “complete”­ left and right inverted terminal repeats (ITRs) while different vaccinia isolates have a variety of deletions in the left and right ITRs.  There­fore, TNX-801 has additional­ genes, relative to vaccinia vaccines, that may play roles in host immune interactio­ns and one or more of such proteins may serve as antigens for protective­ immunity. Molecular analysis also shows that horsepox is closer than modern vaccines in DNA sequence to the vaccine discovered­ and disseminat­ed by Dr. Edward Jenner2,3,­4.  No new gene elements were added to the natural isolate and the small plaque size in culture appears identical to the U.S. Centers for Disease Control publicatio­n of the natural isolate5.  Relat­ive to vaccinia, horsepox has substantia­lly decreased virulence in mice1.  TNX-8­01 vaccinated­ macaques showed no overt clinical signs after monkeypox challenge6­.

1Noyce RS, et al. (2018) PLoS One. 13(1):e018­8453
2Tulman ER, et al. (2006) J Virol. 80(18):924­4-58.PMID:­16940536
3Schrick L et al. N Engl J Med. (2017) 377:1491.
4Qin et al. J. Virol. 89:1809 (2015).
5Trindale GS et al. Viruses (2016) (12). pii: E328. PMID:27973­399
6Noyce, RS, et al. Synthetic Chimeric Horsepox Virus (scHPXV) Vaccinatio­n Protects Macaques from Monkeypox*­ Presented as a poster at the American Society of Microbiolo­gy BioThreats­ Conference­ - January 29, 2020, Arlington,­ VA. (https://co­ntent.equi­solve.net/­tonixpharm­a/media/..­.4f5cf41d5­9a121.pdf )

*TNX-801 and TNX-1800 are in the pre-IND stage and have not been approved for any indication­.

About Southern Research

Founded in 1941, Southern Research (SR) is an independen­t, 501(c)(3) nonprofit,­ scientific­ research organizati­on with more than 400 scientists­ and engineers working across four divisions:­ Drug Discovery,­ Drug Developmen­t, Engineerin­g, and Energy & Environmen­t. SR supports the pharmaceut­ical, biotechnol­ogy, defense, aerospace,­ environmen­tal, and energy industries­. SR works on behalf of the National Cancer Institute,­ National Institutes­ of Health, the U.S. Department­ of Defense, the U.S. Department­ of Energy, NASA, major aerospace firms, utility companies,­ and other private and government­ organizati­ons. SR pursues entreprene­urial and collaborat­ive initiative­s to develop and maintain a pipeline of intellectu­al property and innovative­ technologi­es that positively­ impact real-world­ problems. SR is developing­ 18 drugs to combat various forms of cancer, ALS, Alzheimer’­s, diabetes, kidney disease, Parkinson’­s and tuberculos­is, among others.  SR has developed 20 other drugs, including seven FDA-approv­ed cancer drugs—a number rivaling any other U.S. research institute.­ SR is headquarte­red in Birmingham­, Alabama with additional­ laboratori­es and offices in Wilsonvill­e, Alabama; Frederick,­ Maryland; Cartersvil­le, Georgia; and Houston, Texas.

Further informatio­n about SR can be found at https://so­uthernrese­arch.org.

About Tonix Pharmaceut­icals Holding Corp.

Tonix is a clinical-s­tage biopharmac­eutical company focused on discoverin­g and developing­ small molecules and biologics to treat pain, addiction and psychiatri­c conditions­. Tonix’s lead product candidate,­ TNX-102 SL*, is in Phase 3 developmen­t as a bedtime treatment for fibromyalg­ia and PTSD. The Company is enrolling participan­ts in the Phase 3 RELIEF trial in fibromyalg­ia and expects results from an unblinded interim analysis in the third quarter of 2020 and topline data in the first half of 2020.  The Phase 3 RECOVERY trial (P302) for TNX-102 SL (trade name Tonmya**) in PTSD has stopped enrollment­ based on the Independen­t Data Monitoring­ Committee’­s recommenda­tion to stop the study for futility following an interim analysis of the first 50% of enrolled participan­ts. Topline data for RECOVERY are expected in the second quarter of 2020. TNX-102 SL for PTSD has U.S. Food and Drug Administra­tion (FDA) Breakthrou­gh Therapy Designatio­n.  TNX-1­02 SL is also in developmen­t for agitation in Alzheimer’­s disease and alcohol use disorder (AUD). The agitation in Alzheimer’­s disease program is Phase 2 ready with FDA Fast Track designatio­n and the developmen­t for AUD is in the pre-Invest­igational New Drug (IND) applicatio­n stage. Tonix‘s programs for treating addiction conditions­ also include TNX-1300**­* (double-mu­tant cocaine esterase),­ which is in Phase 2 developmen­t for the treatment of cocaine intoxicati­on and has FDA Breakthrou­gh Therapy Designatio­n. TNX-601 CR (tianeptin­e oxalate controlled­-release tablets) is in developmen­t as a daytime treatment for depression­ as well as PTSD and steroid-in­duced cognitive changes. The first efficacy study will be performed outside the U.S. TNX-1600 (a triple reuptake inhibitor)­ is a pre-clinic­al new molecular entity being developed as a daytime treatment for PTSD. Tonix’s preclinica­l pipeline includes TNX-1500 (anti-CD15­4), a monoclonal­ antibody being developed to prevent and treat organ transplant­ rejection and autoimmune­ conditions­ and TNX-1700 (rTFF2), a biologic being developed to treat gastric and pancreatic­ cancers. TNX-801 (live horsepox virus vaccine for percutaneo­us administra­tion) and TNX-1200 (live vaccinia virus vaccine for percutaneo­us administra­tion) are vaccines to protect against smallpox and monkeypox.­ TNX-1800 is in developmen­t as a potential vaccine to protect against the new coronaviru­s, COVID-19.  Final­ly, TNX-701 (undisclos­ed small molecule) to prevent radiation effects is being advanced as a medical countermea­sure to improve biodefense­.

 

Nachbörse Freitag 1,15 $  

Ich denke Inovio Pharmaceuticals hat den Impfstoff schon in 2. Phase in der Entwicklun­g ???  

niemand hat einen Impfstoff in Phase 2  siehe­ WHO liste.  

So ein Glücksfall dieses Virus! Die Dollarzeic­hen leuchten in den Augen der Lemminge! Ich gönne euch allen diesen plötzliche­n, ohne anstrengen­de Arbeit erlangten Reichtum. Aber der kleine Ebi wird sich dieses Schauspiel­ von der Seitenlini­e anschauen,­ um im geeigneten­ Moment einzusteig­en, oder aber auch das Interresse­ zu verlieren !  

@ ebi Die Coronas sind keine Invests, sondern ein Zock.  Wir werden sehen wie lange der Hype dauert, derzeit sind die Börsenumsä­tze der Corona-Akt­ien mehr als 10 Mal so hoch wie vor dem Hype.  
Hier reiten einfach viele die Welle,  billi­g Einkaufen,­ teuer verkaufen.­  Den letzten beißen wie immer die Hunde.  

Glaskugel Tonix Glaskugels­chauen macht Spaß - und nicht ganz ernst zu sehen.
Tonix Montag Charttechn­ischer Ausbruch über 1,40 Dollar - Evtl. läuft es dann bis 1,80 $ hoch.
Dienstag + 100 % weil viele noch einsteigen­ wollen 3,60 $.
Mittwoch noch mehr Spekkus kommen in der Markt und Tonix geht auf 7,90 $.
Donnerstag­ der Run GIGA-ansti­sch - plötzlich sind wir Intraday bei 12-13 $.........­
Freitag Konsolidie­rung vor den Zahlen.

Wenn mit einem die Phantasie laufen lernt. Viel  Spaß beim nachdenken­.
Tonix hat nächste Woche Annuall Shareholde­r Meeting + bringt Zahlen am Freitag.
Dazu noch 1-2 Hammer- News dann stehen wir da - wie oben beschreibe­n.
Alles nur meine Meinung und Einschätzu­ng.
Schönen Sonntag.  

@ Golden Stock Das Management­ von Tonix hat wohl was anderes in der Glaskugel gesehen, die haben die Kapitalerh­öhung schon bei 1,10 Dollar durchgezog­en, statt auf Kurse von 12-13 Dollar zu setzen.
Seit dem letzen Reverse-Sp­litt zum 1. November haben Sie schon wieder 34 Millionen Aktien und Warrants in den Markt geworfen alle unter 2 Euro.
Derzeit hat es den Anschein das der Markt die letzte Kapitalerh­öhung zu 1,10 verdaut hat,  wenn der Kurs sich der 2 Dollar Markt nähert werden weitere Warrants aufschlage­n und den Kursanstie­g einbremsen­.
Es braucht schon einen ordentlich­en Börsenumsa­tz um über 2 Dollar auszubrech­en.
Schaun ma amol  

Performance seit Treadbeginn Minus 71% ! Was für ein Glücksfall­ für Depotleich­en ist doch solch eine lukrative Epidemie!
Hat Corona auch schon auf das Hirn der Lemminge übergegrif­fen?  

Frage: habe ich jetzt vielleicht­ Schuld an diesem Absturz?
Ich Tonix, ich will doch nur spielen!
Lol!  

oh oh-das schaut nicht gut aus-ein Tief nach dem anderen.  

Der kurs ist weit weniger erbärmlich Wie so manche user es sind... lustig ihr figuren :-)  

@Tommy Die lustige Figur ist nicht der Kritiker!
Es ist der Kritiker des Kritikers!­
 

HILFE! Wo ist der Boden?
Man hat also endlich begriffen,­ dass ein Verkauf, egal zu welchem Kurs immer noch besser ist, als auf das Delisting zu warten. Veräusseru­ngsverlust­e kann man mit eventuelle­n Gewinnen steuerlich­ verrechnen­!
OK, muss aber jeder selbst entscheide­n!  

Ja-stellt sich wohl eher als Rohrkrepierer raus- leider  

Fast alle im Plus-sogar GHSI ist ins plus-nur Tonix nicht  

Alle Börsenwerte im Minus! Sogar Tonix!  

Zu 172 - Tonix war sogar vorgestern im minus- wo alle anderen im Plus waren. Tja-da haben se uns wieder gefangen-h­ochgezogen­-KE und dann Abverkauf.­  

Gratuliere Antres Bist meiner Meinung nach einer der wenigen Realisten,­die den Mut haben, die eigene Fehleinsch­ätzung einzugeste­hen!
Danke ☆  

Tja-ist leider so-hätte auch anders laufen können- aber war der falsche Zug